2026 Third Medical Aesthetic Device Industry Conference
"2026 Third Medical Aesthetic Device Industry Conference", organized by Youer Medical Device Service Platform, was held at Shanghai Dahua Hongqiao Holiday Hotel on May 26, 2026. Wang Peng, Consulting Director of Frost & Sullivan Frost & Sullivan China’s Health Care Division, was invited to attend and delivered a speech.
Wang Peng, Consulting Director of Frost & Sullivan China’s Health Care Division
Wang Peng pointed out that current medical aesthetic injection products mainly include hyaluronic acid, collagen, regenerative materials, and botulinum toxin. Among them, the collagen sector is undergoing significant changes. Collagen can be divided into animal-derived collagen and recombinant collagen. Animal-derived collagen is derived from by-products of animal slaughter such as tendons and skin, resulting in relatively low production costs. With the development of advanced extraction, purification, and immunogenic removal technologies, the biocompatibility of the material improves and the risk of allergies decreases. Animal-derived collagen is used in hemostatic materials and artificial dermal products, while some companies are developing it for medical aesthetic injections. Recombinant collagen is produced by engineering humanized collagen genes, followed by enzymatic digestion and splicing into engineered cells for expression. It usually has higher purity and stability and lower immunogenicity, but the production process is complex and the entry barriers are high. Wang Peng emphasized that recombinant humanized collagen has become an important innovation direction in medical aesthetic injections. In 2021, Jinbo Biotech’s recombinant type III humanized collagen freeze-dried fibers were approved for market, becoming the first recombinant type III product for medical aesthetic injections in China. In 2023, the product sold over 570,000 bottles, a 251.69% increase year-on-year. Juzi Biotech and Chuangjian Medical are also actively applying for approvals. With capital support, Juyuan Biotech completed three rounds of financing and received over 200 million yuan in Series B financing for medical services. Many companies are entering the market, and the competitive landscape is constantly changing.
Regarding regenerative preparation materials, Wang Peng said that these materials achieve aesthetic effects by stimulating the regeneration of human collagen, offering advantages such as long-lasting effects, natural results, and biodegradability. Exosomes, as nanoscale vesicles secreted by cells, serve as important carriers for cell-to-cell communication, transporting various bioactive substances such as proteins, nucleic acids, and lipids. They play a key role in tissue repair and regeneration and are considered important links between regenerative medicine and medical aesthetics. Research on exosomes in China mainly focuses on skin repair and regenerative medicine. Current clinical studies are still in the early exploration stage, and the overall progress is in transition from mechanism verification to clinical application.
In recent years, breakthroughs have been made in new biological medical aesthetic materials: silk fibroin became the first Class III device and industry standards were established; chitosan, the world’s first non-animal-derived medical aesthetic filler, is expected to receive CE certification in 2025; agarose (Algeness) and domestic/imported hydroxyapatite fillers (such as Youlan and Rudexi) were approved for market in 2025, promoting standardized and diversified development in the industry. In medical aesthetic applications, ECM and PDRN, as two biologically active materials, exhibit different mechanisms and compliance development paths. ECM is a natural three-dimensional scaffold prepared from animal tissues via decellularization, primarily composed of collagen and glycosaminoglycans, which simulates the microenvironment where cells grow in the body, providing structural support for tissue repair. Synthetic biology technology uses recombinant expression pathways to prevent immunogenicity at the source, combined with engineered cross-linking modifications, making the degradation and tissue regeneration rates within the body coordinated and controllable, thus establishing a solid technical foundation for large-scale production and full-lifecycle quality control. PDRN is a deoxyribonucleotide polymer extracted and purified from salmon sperm glands. In medical aesthetic applications, PDRN is often used to improve skin texture, assist barrier repair, and reduce discomfort during recovery after inflammation. Although there are no relevant Class III medical device injection products approved by the National Medical Products Administration in the domestic market, many companies are already preparing such products.
Finally, Wang Peng noted that breakthroughs in new materials, development of new technologies, and introduction of new concepts are providing more ideas for "beautifying" the market and consumers. Precision medicine promotes customized "beautifying" solutions, combining genetic testing and AI analysis to create personalized treatment plans based on individual skin type, genetic predisposition, and allergy history. The continuous emergence of new materials and products is leading new trends in the medical aesthetics industry, such as the research and development of exosomes and stem cells as anti-aging medical aesthetic products, and the expansion of indications for ultrasound beams, gold microneedles, and Thermage among acoustic and optoelectronic treatment devices. Additionally, the combination of medical aesthetics and health management is leading to one-stop health beauty management centers, helping consumers achieve scientific beautification.
